What are the current treatment guidelines for Helicobacter pylori infection?

Current Treatment Guidelines for Helicobacter pylori Infection

Due to rising antibiotic resistance, empiric clarithromycin-based triple therapy should be abandoned, and first-line treatment should be either bismuth quadruple therapy or concomitant non-bismuth quadruple therapy for 14 days. 1, 2

First-Line Treatment Approach

Preferred Regimens (Choose Based on Local Resistance and Availability)

Bismuth Quadruple Therapy (PBMT) - Preferred Option:

• PPI (e.g., pantoprazole 40 mg) twice daily + bismuth subsalicylate ~300 mg four times daily + metronidazole 500 mg 3-4 times daily + tetracycline 500 mg four times daily for 14 days 2, 3
• This regimen is particularly favored in areas with high dual resistance to clarithromycin and metronidazole, and it maintains acceptable success even with metronidazole-resistant strains 2
• All three major consensus groups (Toronto, Maastricht V/Florence, ACG) recommend this as first-line therapy 2

Concomitant Non-Bismuth Quadruple Therapy (PAMC) - Alternative First-Line:

• PPI (e.g., pantoprazole 40 mg) twice daily + amoxicillin 1000 mg twice daily + metronidazole 500 mg twice daily + clarithromycin 500 mg twice daily for 14 days 2, 3
• Appropriate for areas of high clarithromycin resistance where bismuth is unavailable 2

When Traditional Triple Therapy May Still Be Used (Restricted Circumstances)

PPI triple therapy is only acceptable when:

• Clarithromycin resistance is documented to be <15% locally, OR
• Local proven eradication rates exceed 85% with this regimen, OR
• The patient is from an area with known low clarithromycin resistance AND has no previous macrolide exposure 2

If these criteria are met: PPI twice daily + clarithromycin 500 mg twice daily + amoxicillin 1000 mg twice daily for 14 days 2

Critical Treatment Duration

All first-line regimens should be given for 14 days to maximize first-attempt success, avoiding retreatment costs, patient anxiety, and negative impacts on gut microbiota 2, 4

Penicillin Allergy Considerations

• If true penicillin allergy exists: Use bismuth quadruple therapy (PBMT) as first-line 2
• After first-line failure in penicillin-allergic patients: Refer for allergy testing, as most patients reporting penicillin allergy do not have true allergy 2

Second-Line (Rescue) Treatment After First Failure

The choice depends on what was used previously - never reuse clarithromycin or levofloxacin if previously exposed: 2

If first-line was clarithromycin-containing:

• Bismuth quadruple therapy (PBMT) for 14 days 2
• Levofloxacin triple therapy: PPI twice daily + amoxicillin 1000 mg twice daily + levofloxacin 500 mg once daily for 14 days 2, 3

If first-line was bismuth quadruple or metronidazole-containing:

• Levofloxacin triple therapy for 14 days 2

Important caveat: Levofloxacin resistance is rapidly increasing, so susceptibility testing should be strongly considered at this stage 2

Third-Line (Salvage) Treatment After Two Failures

Culture with antimicrobial susceptibility testing is strongly recommended after second-line failure, though not widely available in North America 2

Empiric options include:

• High-dose dual therapy: PPI 80 mg twice daily + amoxicillin 2-3 g daily (divided into 3-4 doses) for 14 days 2, 3
• Bismuth quadruple therapy (if not previously used) 2
• Concomitant therapy (if high dual clarithromycin/metronidazole resistance) 2

Fourth-Line Treatment (After Three Failures)

Rifabutin-containing regimen: PPI twice daily + amoxicillin 1000 mg twice daily + rifabutin 150 mg twice daily for 14 days 2

• This should be restricted to patients who have failed at least 3 prior regimens due to potential myelotoxicity 2

Critical Antibiotic Stewardship Principles

Never reuse these antibiotics if previously exposed:

• Clarithromycin - resistance develops rapidly after exposure 1, 2, 3
• Levofloxacin - resistance develops rapidly after exposure 1, 2, 3

May be reused:

• Metronidazole - can be reused when combined with bismuth due to synergistic effects 2, 3
• Amoxicillin - resistance remains rare 2
• Tetracycline - resistance remains rare 2

PPI Administration Guidelines

PPIs should be taken 30 minutes before meals on an empty stomach 3 Avoid concomitant use of H2-receptor antagonists 3

Key Paradigm Shifts in Current Guidelines

The 2022 Annual Review of Medicine and 2019 consensus reconciliation emphasize that traditional clarithromycin, metronidazole, and levofloxacin triple therapies should be abandoned for empiric use due to increasing antimicrobial resistance 1, 2. This represents a major departure from 1990s practice when 7-10 day triple therapies achieved 90% eradication rates 2. Success rates have declined substantially, necessitating these changes 1, 2.

Common Pitfalls to Avoid

• Do not use 7-10 day regimens - 14 days is now standard for all regimens 2, 4
• Do not use clarithromycin empirically unless local resistance is documented <15% 1, 2
• Do not use levofloxacin as first-line - reserve for rescue therapy 2
• Do not repeat the same antibiotic combination that previously failed 2
• Do not forget to confirm eradication - testing should be performed after treatment, particularly for peptic ulcer disease, persistent symptoms, MALT lymphoma, or after gastric cancer resection 5